Solanezumab trial fails

The clinical trial of key Alzheimer's drug solanezumab has failed, Eli Lilly has announced But this is not the end for beta amyloid theory, one expert says. Eli Lilly made the announcement yesterday that solanezumab did not slow down cognitive decline in patients with Alzheimer’s compared to those who took placebo. Solanezumab targeted beta amyloid—the protein that